gdc

Leukemia

Drugs for Leukemia
Leukemia
Find financial assistance programs available for leukemia drugs.
Tecartus, a Gene Therapy, Now Approved for Patients with Relapsed B-Cell Precursor Acute Lymphoblastic Leukemia
FDA Approvals, News & UpdatesLeukemia
In October 2021, the FDA approved a second indication for Tecartus (brexucabtagene autoleucel), a novel, genetically modified CAR T-cell therapy, for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia.
Scemblix a New Oral Therapy Approved for Patients with Chronic Myeloid Leukemia
FDA Approvals, News & UpdatesLeukemia
In October 2021, the FDA approved Scemblix (asciminib) for patients with chronic-phase Ph-positive chronic myeloid leukemia (CML) or CML associated with T315I mutation. Scemblix is a new type of drug that may improve outcomes over other therapies for some patients with CML.
Fighting Is the Hard Part, but You Have to Try
CaregiversSurvivorshipLeukemia
At age 84, Inocencio Melendez-Schroder was diagnosed with stage IV leukemia and was told that chemotherapy and radiation would not be recommended. Soon after his death at home, his daughter, Barbara, was diagnosed with stage II leukemia and used her dad’s lessons to improve her prognosis.
Combining Targeted Therapies in CLL
CLL Monthly MinutesLeukemia
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL.
A Comprehensive Analysis of COVID-19 in Patients with CLL
CLL Monthly MinutesLeukemia
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL.
Infections in Patients with CLL Receiving Ibrutinib
CLL Monthly MinutesLeukemia
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients.
Page 1 of 13
Results 1 - 10 of 126

Subscribe to CONQUER: the patient voice

Receive timely cancer news & updates, patient stories, and more.


Country
Race or Ethnicity
Gender
Profession or Role
Primary Interest